文献速递艾滋病与性传播感染

基于多替拉韦的维持单药治疗与联合拉米夫定的双药治疗比较:DOLAM随机临床试验的计划24周分析

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

DOLAM开放标签非劣效随机试验计划24周分析,91例病毒载量<50拷贝/mL≥12个月的HIV-1感染者随机分为三药维持组、多替拉韦/拉米夫定组和多替拉韦单药组。多替拉韦单药组出现2例病毒学失败并伴整合酶交叉耐药突变,数据安全监察委员会建议停止该组;多替拉韦/拉米夫定组1例失败无耐药突变。

要点

  • 多替拉韦单药维持治疗出现高于预期的病毒学失败风险,并伴整合酶交叉耐药突变。
  • 数据安全监察委员会建议停止多替拉韦单药治疗组。
  • 多替拉韦/拉米夫定组1例病毒学失败,未检出耐药突变。

核心结论

  • 与多替拉韦/拉米夫定相比,多替拉韦维持单药治疗出现高于预期的病毒学失败风险,并伴整合酶交叉耐药突变的产生。

研究设计与样本

  • 开放标签非劣效随机对照试验,分两阶段:A阶段检验实验组失败率是否不可接受(≥5%),B阶段计划纳入完整数量患者随访48周。
  • 纳入已治疗HIV-1感染成人,病毒载量<50拷贝/mL持续≥12个月,无既往病毒学失败或对研究药物耐药突变,CD4最低值>200细胞/mm3,乙型肝炎病毒表面抗原阴性。
  • 按1:1:1随机分配至维持三药治疗(对照组)、换用多替拉韦/拉米夫定或多替拉韦单药治疗,按锚定药物分层。
  • 共91例随机(对照组n=31;双药治疗组n=29;单药治疗组n=31)。
  • 此处报告计划中的A阶段24周结果。

主要发现

  • 3例患者因病毒学失败提前终止治疗:多替拉韦/拉米夫定组1例(受试者A),无耐药突变;多替拉韦单药组2例,受试者B检出N155H、S147G和Q148R耐药突变,受试者C检出E138K、G140S和N155H耐药突变。
  • 3例病毒学失败者均无既往整合酶抑制剂暴露史。
  • 无因其他原因终止治疗者。
  • 1例患者(多替拉韦/拉米夫定组)出现病毒载量短暂波动。
  • 数据安全监察委员会建议停止多替拉韦单药治疗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these options would have similar efficacy to triple ART. METHODS: We used an open-label non-inferiority randomized controlled trial comprising two phases: phase A was established to test that experimental arms did not have an unacceptable (≥5%) failure rate; phase B was intended to include the full number of patients followed for 48 weeks. Treated HIV-1-infected adults with viral load <50 copies/mL for ≥12 months, no prior viral failure or resistance mutations to study drugs, nadir CD4 >200 cells/mm3, and hepatitis B virus surface antigen negative were randomized 1:1:1 to maintain triple therapy (control arm), or to switch to dolutegravir/lamivudine, or to dolutegravir monotherapy stratifying by anchor drug. Premature discontinuation was considered if viral failure or therapy interruption due to adverse events, concurrent illness, protocol deviation or patient's wish occurred. Blips were registered. Planned phase A results at 24 weeks are reported here. The study is registered at EudraCT: 201500027435. RESULTS: Ninety-one (control, n = 31; dual therapy, n = 29; monotherapy, n = 31) patients were randomized. Three patients (none previously exposed to integrase inhibitors) prematurely discontinued treatment due to viral failure: dolutegravir/lamivudine (n = 1), no resistance mutations (subject A); dolutegravir (n = 2), N155H, S147G and Q148R resistance mutations (subject B), and E138K, G140S and N155H resistance mutations (subject C). There were no discontinuations for other reasons. One patient (dolutegravir/lamivudine) experienced a blip in viral load. The Data Safety Monitoring Board recommended stopping the dolutegravir monotherapy arm. CONCLUSIONS: In contrast to dolutegravir/lamivudine, a higher than expected risk of viral failure with development of cross-resistance integrase mutations occurred with dolutegravir maintenance monotherapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Blanco JL, Rojas J, Paredes R, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018. PMID: 29608685. doi:10.1093/jac/dky093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。